Severe Cholestatic Hepatitis due to Temozolomide: An Adverse Drug Effect to Keep in Mind. Case Report and Review of Literature

Antonio Grieco; Maria Antonietta Tafuri; Marco Biolato; Barbara Diletto; Nicola Di Napoli; Nicola Balducci; Fabio Maria Vecchio; Luca Miele

doi:10.1097/MD.0000000000000476

Severe Cholestatic Hepatitis due to Temozolomide: An Adverse Drug Effect to Keep in Mind. Case Report and Review of Literature

Antonio Grieco, Maria Antonietta Tafuri, Marco Biolato, Barbara Diletto, Nicola Di Napoli, Nicola Balducci, Fabio Maria Vecchio, Luca Miele

Research output: Contribution to journal › Article

Abstract

Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy. Hematologic adverse events are the most frequent side effects of temozolomide, while liver toxicity has been reported only in the post-marketing period.Here we report a case of severe temozolomide-induced liver injury during concurrent radiotherapy treatment, at a dose level of 75 mg/m(2).The aim of this case report is to focus on the problems of temozolomide-induced hepatotoxicity. In conclusion, a close monitoring of liver function tests is recommended during treatment with temozolomide.

Original language	English
Pages (from-to)	e476-N/A
Journal	MEDICINE
Volume	94
DOIs	https://doi.org/10.1097/MD.0000000000000476
Publication status	Published - 2015

Keywords

Aged
Antineoplastic Agents, Alkylating
Brain Neoplasms
Chemical and Drug Induced Liver Injury
Cholestasis
Dacarbazine
Fatal Outcome
Glioblastoma
Humans
Male
Temozolomide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/MD.0000000000000476

Cite this

@article{6fa36a1cac1f438491fd058f985f251a,

title = "Severe Cholestatic Hepatitis due to Temozolomide: An Adverse Drug Effect to Keep in Mind. Case Report and Review of Literature",

abstract = "Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy. Hematologic adverse events are the most frequent side effects of temozolomide, while liver toxicity has been reported only in the post-marketing period.Here we report a case of severe temozolomide-induced liver injury during concurrent radiotherapy treatment, at a dose level of 75 mg/m(2).The aim of this case report is to focus on the problems of temozolomide-induced hepatotoxicity. In conclusion, a close monitoring of liver function tests is recommended during treatment with temozolomide.",

keywords = "Aged, Antineoplastic Agents, Alkylating, Brain Neoplasms, Chemical and Drug Induced Liver Injury, Cholestasis, Dacarbazine, Fatal Outcome, Glioblastoma, Humans, Male, Temozolomide, Aged, Antineoplastic Agents, Alkylating, Brain Neoplasms, Chemical and Drug Induced Liver Injury, Cholestasis, Dacarbazine, Fatal Outcome, Glioblastoma, Humans, Male, Temozolomide",

author = "Antonio Grieco and Tafuri, {Maria Antonietta} and Marco Biolato and Barbara Diletto and {Di Napoli}, Nicola and Nicola Balducci and Vecchio, {Fabio Maria} and Luca Miele",

year = "2015",

doi = "10.1097/MD.0000000000000476",

language = "English",

volume = "94",

pages = "e476--N/A",

journal = "MEDICINE",

issn = "0025-7974",

publisher = "-Wolters Kluwer Health, -Philadelphia : Lippincott, Williams & Wilkins",

}

TY - JOUR

T1 - Severe Cholestatic Hepatitis due to Temozolomide: An Adverse Drug Effect to Keep in Mind. Case Report and Review of Literature

AU - Grieco, Antonio

AU - Tafuri, Maria Antonietta

AU - Biolato, Marco

AU - Diletto, Barbara

AU - Di Napoli, Nicola

AU - Balducci, Nicola

AU - Vecchio, Fabio Maria

AU - Miele, Luca

PY - 2015

Y1 - 2015

N2 - Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy. Hematologic adverse events are the most frequent side effects of temozolomide, while liver toxicity has been reported only in the post-marketing period.Here we report a case of severe temozolomide-induced liver injury during concurrent radiotherapy treatment, at a dose level of 75 mg/m(2).The aim of this case report is to focus on the problems of temozolomide-induced hepatotoxicity. In conclusion, a close monitoring of liver function tests is recommended during treatment with temozolomide.

AB - Temozolomide is the current standard of therapy for postoperative patients with glioblastoma starting adjuvant radiotherapy. Hematologic adverse events are the most frequent side effects of temozolomide, while liver toxicity has been reported only in the post-marketing period.Here we report a case of severe temozolomide-induced liver injury during concurrent radiotherapy treatment, at a dose level of 75 mg/m(2).The aim of this case report is to focus on the problems of temozolomide-induced hepatotoxicity. In conclusion, a close monitoring of liver function tests is recommended during treatment with temozolomide.

KW - Aged

KW - Antineoplastic Agents, Alkylating

KW - Brain Neoplasms

KW - Chemical and Drug Induced Liver Injury

KW - Cholestasis

KW - Dacarbazine

KW - Fatal Outcome

KW - Glioblastoma

KW - Humans

KW - Male

KW - Temozolomide

KW - Aged

KW - Antineoplastic Agents, Alkylating

KW - Brain Neoplasms

KW - Chemical and Drug Induced Liver Injury

KW - Cholestasis

KW - Dacarbazine

KW - Fatal Outcome

KW - Glioblastoma

KW - Humans

KW - Male

KW - Temozolomide

UR - http://hdl.handle.net/10807/220235

U2 - 10.1097/MD.0000000000000476

DO - 10.1097/MD.0000000000000476

M3 - Article

SN - 0025-7974

VL - 94

SP - e476-N/A

JO - MEDICINE

JF - MEDICINE

ER -

Severe Cholestatic Hepatitis due to Temozolomide: An Adverse Drug Effect to Keep in Mind. Case Report and Review of Literature

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this